trending Market Intelligence /marketintelligence/en/news-insights/trending/e4Ao-QtvdM2Am4FvvXC69A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Pfizer-Astellas' Xtandi gets US FDA supplemental approval for prostate cancer

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Pfizer-Astellas' Xtandi gets US FDA supplemental approval for prostate cancer

Pfizer Inc. and Astellas Pharma Inc. said the U.S. Food and Drug Administration approved Xtandi to treat a type of prostate cancer.

The regulator approved the companies' supplemental new drug application for Xtandi to treat metastatic castration-sensitive prostate cancer, a type of the disease in which the cancer has spread beyond the prostate and still responds to therapy to lower testosterone levels.

The drug, also known as enzalutamide, was previously approved to treat two other advanced types of the disease: Non-metastatic and metastatic castration-resistant prostate cancer.

The new approval is based on results from a phase 3 study called Arches, in which patients who received both the drug and hormone therapy lived longer without the disease worsening than those who received only the therapy.

New York's Pfizer jointly markets Xtandi in the U.S. with Tokyo-based Astellas, which commercializes the drug elsewhere.